Teleflex Stock Forecast, Price & News

Teleflex (NYSE:TFX) Frequently Asked Questions

Is Teleflex a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Teleflex in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Teleflex stock.
View analyst ratings for Teleflex or view top-rated stocks.

How has Teleflex's stock price been impacted by Coronavirus?

Teleflex's stock was trading at $342.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TFX shares have decreased by 5.5% and is now trading at $323.28.
View which stocks have been most impacted by COVID-19.

Are investors shorting Teleflex?

Teleflex saw a increase in short interest during the month of October. As of October 29th, there was short interest totaling 738,700 shares, an increase of 25.8% from the October 14th total of 587,400 shares. Based on an average daily trading volume, of 272,700 shares, the days-to-cover ratio is presently 2.7 days. Currently, 1.6% of the shares of the stock are sold short.
View Teleflex's Short Interest.

When is Teleflex's next earnings date?

Teleflex is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Teleflex.

How were Teleflex's earnings last quarter?

Teleflex Incorporated (NYSE:TFX) announced its earnings results on Thursday, October, 28th. The medical technology company reported $3.51 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.48. The medical technology company earned $700.25 million during the quarter, compared to analysts' expectations of $698.25 million. Teleflex had a trailing twelve-month return on equity of 17.78% and a net margin of 15.71%. The company's quarterly revenue was up 11.5% on a year-over-year basis. During the same period in the previous year, the business earned $2.77 EPS.
View Teleflex's earnings history.

How often does Teleflex pay dividends? What is the dividend yield for Teleflex?

Teleflex announced a quarterly dividend on Thursday, October 28th. Investors of record on Monday, November 15th will be given a dividend of $0.34 per share on Wednesday, December 15th. This represents a $1.36 dividend on an annualized basis and a yield of 0.42%. The ex-dividend date is Friday, November 12th.
View Teleflex's dividend history.

Is Teleflex a good dividend stock?

Teleflex pays an annual dividend of $1.36 per share and currently has a dividend yield of 0.42%. The dividend payout ratio of Teleflex is 14.86%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Teleflex will have a dividend payout ratio of 9.51% next year. This indicates that Teleflex will be able to sustain or increase its dividend.
View Teleflex's dividend history.

What guidance has Teleflex issued on next quarter's earnings?

Teleflex issued an update on its FY 2021 earnings guidance on Thursday, November, 4th. The company provided EPS guidance of $13.150-$13.350 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $12.980. The company issued revenue guidance of $2.79 billion-$2.82 billion, compared to the consensus revenue estimate of $2.82 billion.

What price target have analysts set for TFX?

10 brokerages have issued 1 year target prices for Teleflex's shares. Their forecasts range from $391.00 to $486.00. On average, they expect Teleflex's share price to reach $445.20 in the next twelve months. This suggests a possible upside of 37.7% from the stock's current price.
View analysts' price targets for Teleflex or view top-rated stocks among Wall Street analysts.

Who are Teleflex's key executives?

Teleflex's management team includes the following people:

• Liam J. Kelly, Chairman, President & Chief Executive Officer
• Thomas E. Powell, Chief Financial Officer & Executive Vice President
• Timothy F. Duffy, Chief Information Officer & Vice President
• Michelle Fox, Chief Medical Officer & Vice President
• Gwen Chapman, Chief Compliance Officer & Vice President

What is Liam Kelly's approval rating as Teleflex's CEO?

73 employees have rated Teleflex CEO Liam Kelly on Glassdoor.com. Liam Kelly has an approval rating of 86% among Teleflex's employees.

Who are some of Teleflex's key competitors?

Some companies that are related to Teleflex include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Edwards Lifesciences (EW), Becton, Dickinson and (BDX), Boston Scientific (BSX), DexCom (DXCM), IDEXX Laboratories (IDXX), Baxter International (BAX), ResMed (RMD), STERIS (STE), Hologic (HOLX), Insulet (PODD) and Masimo (MASI).
View all of TFX's competitors.

What other stocks do shareholders of Teleflex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teleflex investors own include NVIDIA (NVDA), AbbVie (ABBV), Johnson & Johnson (JNJ), Alibaba Group (BABA), Lam Research (LRCX), ServiceNow (NOW), QUALCOMM (QCOM), Advanced Micro Devices (AMD), salesforce.com (CRM) and Cisco Systems (CSCO).

What is Teleflex's stock symbol?

Teleflex trades on the New York Stock Exchange (NYSE) under the ticker symbol "TFX."

Who are Teleflex's major shareholders?

Teleflex's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.20%), Wellington Management Group LLP (6.97%), American Century Companies Inc. (2.83%), Janus Henderson Group PLC (1.98%), Geode Capital Management LLC (1.75%) and Marshall Wace LLP (1.47%). Company insiders that own Teleflex stock include Andrew A Krakauer, Cameron P Hicks, James J Leyden, John Deren, Liam Kelly, Stephen K MD Klasko and Stuart A Randle.
View institutional ownership trends for Teleflex.

Which institutional investors are selling Teleflex stock?

TFX stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, BlackRock Inc., Invesco Ltd., Janus Henderson Group PLC, Bank of New York Mellon Corp, Allianz Asset Management GmbH, Strs Ohio, and Sectoral Asset Management Inc. Company insiders that have sold Teleflex company stock in the last year include Cameron P Hicks, Liam Kelly, Stephen K MD Klasko, and Stuart A Randle.
View insider buying and selling activity for Teleflex or view top insider-selling stocks.

Which institutional investors are buying Teleflex stock?

TFX stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Wellington Management Group LLP, Moors & Cabot Inc., Moors & Cabot Inc., Sarasin & Partners LLP, NFJ Investment Group LLC, Voloridge Investment Management LLC, and Polar Capital Holdings Plc.
View insider buying and selling activity for Teleflex or or view top insider-buying stocks.

How do I buy shares of Teleflex?

Shares of TFX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Teleflex's stock price today?

One share of TFX stock can currently be purchased for approximately $323.28.

How much money does Teleflex make?

Teleflex has a market capitalization of $15.14 billion and generates $2.54 billion in revenue each year. The medical technology company earns $335.32 million in net income (profit) each year or $9.15 on an earnings per share basis.

How many employees does Teleflex have?

Teleflex employs 14,000 workers across the globe.

When was Teleflex founded?

Teleflex was founded in 1943.

What is Teleflex's official website?

The official website for Teleflex is www.teleflex.com.

Where are Teleflex's headquarters?

Teleflex is headquartered at 550 E SWEDESFORD RD, WAYNE PA, 19087.

How can I contact Teleflex?

Teleflex's mailing address is 550 E SWEDESFORD RD, WAYNE PA, 19087. The medical technology company can be reached via phone at (610) 225-6800, via email at [email protected], or via fax at 215-553-5402.